

Neopharma Technologies, Ltd. Announces Proposed Offerings of Mandatory Convertible Preferred Stock

March 10, 2025

LOS ANGELES, California – March 10, 2025 /PRNewswire/ -- Neopharma Technologies, Inc., announced today that it intends to offer up to \$5 Million USD of its Pre-IPO Mandatory Convertible Preferred Stock ("Preferred Stock"). The Preferred Stock will be offered to residents of the State of California Investors who are each a “Qualified Purchaser” as defined in the SEC Section CE and California Section 25102(n), and to investors of the other 49 States who are each an “Accredited Investor” as defined under Rule 501(a) of Regulation D. Preferred Stock may also be offered to non-U.S. residents who meet the criteria of Regulation S. The Pre-IPO Offering is expected to close within ninety (90) days but may be extended by thirty (30) days by the management of Neopharma Technologies, Ltd.

Details about the Company can be found at www.NeopharmaTechnologies.com; and details about the Pre-IPO offering of Preferred Stock can be found at www.NeopharmaTechnologiesIR.com.

About the Company:

Neopharma Technologies Ltd is an Australian public company that participates in the multi-billion-dollar global Point-of-Care Health Testing markets.

Neopharma aims to be a global leader in these markets with its NEOVAULT® paperless testing solution. Individual test kits are paired with the NEOVAULT® Digital Testing Platform via a unique QR code printed onto each individual test kit.

Neopharma Technologies is revolutionizing the AI Empowered Rapid Diagnostics industry with its innovative NEOVAULT® platform. This cutting-edge solution combines artificial intelligence, cognitive assessment tools, and comprehensive data analysis to transform diagnostic testing across multiple sectors. By addressing critical challenges in workplace safety, healthcare, and beyond, Neopharma Technologies is poised to capture a significant share of a \$4.2 billion total addressable market.

Neopharma’s global growth strategy includes partnering with the largest manufacturers of Drug Test Kits that already have sales of millions of test kits annually. Neopharma has also developed a range of Point-of-Care (POC) rapid tests that pair with Neopharma’s digital health testing platform NEOVAULT®.

Neopharma Technologies is intending to list on to a US OTC exchange as a first step towards a subsequent NASDAQ listing after the commercialization and global roll out of it NEOVAULT® Digital Drug and Impairment Testing Platform this year.

Neopharma is currently preparing for the enablement of the first 5million drug test kits at the point of manufacture, with a weighted pipeline of over 100 million QR codes (and growing) over the next few years.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond NEOPHARMA TECHNOLOGIES, LTD.'S control. Forward-looking statements are statements that are not historical facts and generally can be identified by the use of such words as "becoming," "may," "will," "should," "could," "would," "predict," "potential," "continue," "anticipate," "believe," "estimate," "seek," "expect," "plan," "intend," the negative of such words or comparable terminology. Although NEOPHARMA TECHNOLOGIES, LTD. believes that the expectations reflected in NEOPHARMA TECHNOLOGIES, LTD.'s forward-looking statements are reasonable, NEOPHARMA TECHNOLOGIES, LTD. has based these expectations on its current beliefs as well as its assumptions, and such expectations may not prove to be correct. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of NEOPHARMA TECHNOLOGIES, LTD.'s control. Forward-looking statements related to the offering(s) and NEOPHARMA TECHNOLOGIES, LTD.'s actual results of operations and financial performance could differ significantly from those expressed in or implied by NEOPHARMA TECHNOLOGIES, LTD.'s forward-looking statements. The forward-looking statements included in this disclosure are made only as of the date of this disclosure. NEOPHARMA TECHNOLOGIES, LTD. does not intend, and undertakes no obligation, to update these forward-looking statements.